Control of tumor size and disease activity during cotreatment with octreotide and the growth hormone receptor antagonist pegvisomant in an acromegalic patient.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 11157994.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
We describe the case of an acromegalic subject, who was the first patient ever treated with the GH receptor antagonist pegvisomant. Furthermore, in this particular patient, progression in tumor size was encountered during treatment with pegvisomant. The patient described did benefit from cotreatment with pegvisomant and octreotide, including decreased GH levels, normalization of serum insulin-like growth factor I concentrations, and improvement of visual field defects.
Medical subject headings
- Acromegaly
- Adenoma
- Antineoplastic Agents, Hormonal
- Human Growth Hormone
- Neoplasm Recurrence, Local
- Octreotide
- Pituitary Neoplasms